Baird Capital

Baird Capital is the global private equity and venture arm of Baird, with healthcare investments concentrated in founder-led technology and tech-enabled services companies. The portfolio includes Prescient Healthcare Group and Blue Matter, which together signal an appetite for commercial-strategy, life-sciences-services, and consulting-adjacent businesses. AI is not the explicit thesis; Baird’s edge is its public-company parent’s bench of healthcare advisors, sector bankers, and operating partners who can support founders through scaling and exit.

The firm invests at Series B, Series C, and growth stages with check sizes between $5M and $25M. That makes Baird a candidate for leading growth rounds in healthtech and tech-enabled services where the founder is still operationally engaged and the business has clear revenue traction.

Founders should approach Baird Capital when they run a founder-led healthcare technology or services business with proven unit economics, repeatable customer acquisition, and ambitions for a strategic exit or further growth. Pre-revenue companies, biotech, and pure device plays are not the right fit. Because the firm spans both PE and venture strategies, founders should be explicit about whether they are seeking minority growth capital or a more control-oriented partnership. Expect thorough operational diligence and a partner that thinks about capital structure, M&A roll-ups, and exit timing more than early product iteration. Bring a clean financial model and a clear narrative about how additional capital accelerates the existing trajectory.